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ABSTRACT
Introduction: The Antiretroviral Analysis by
Monte Carlo Individual Simulation (ARAMIS)
model was adapted to evaluate the cost-
effectiveness of dolutegravir (DTG) in Canada
in treatment-naive (TN) and treatment-
experienced (TE) human immunodeficiency
virus (HIV)-1 patients.
Methods: The ARAMIS-DTG model is a
microsimulation model with a lifetime
analytic time horizon and a monthly cycle
length. Markov health states were defined by
HIV health state (with or without opportunistic
infection). DTG was compared to efavirenz
(EFV), raltegravir (RAL), darunavir/ritonavir,
rilpivirine (RPV), elvitegravir/cobicistat,
atazanavir/ritonavir and lopinavir/ritonavir in
TN patients and to RAL in TE patients. The
initial cohort, the main efficacy data and safety
data were derived from phase III clinical trials.
Treatment algorithms were based on expert
opinion. Costs normalized to the year 2013
included antiretroviral treatment cost, testing,
adverse event, HIV and cardiovascular disease
care and were derived from the literature.
Results: Dolutegravir was estimated to be the
dominant strategy compared with all
comparators in both TN and TE patients.
Treatment with DTG was associated with
additional quality-adjusted life-years that
ranged from 0.17 (vs. RAL) to 0.47 (vs. EFV) in
TN patients and was 0.60 in TE patients over a
lifetime. Cost savings ranged from Can$1393
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(vs. RPV) to Can$28,572 (vs. RAL) in TN
patients and amounted to Can$3745 in TE
patients. Sensitivity analyses demonstrated the
robustness of the model.
Conclusions: Dolutegravir is a dominant
strategy in the management of TN and TE
patients when compared to recommended
comparators. This is mainly related to the high
efficacy and high barrier to resistance.
Funding: ViiV Healthcare.
Keywords: Canada; Cost-effectiveness;
Dolutegravir; HIV; Treatment naive
INTRODUCTION
The human immunodeficiency virus (HIV) is a
retrovirus that infects the cells of the immune
system and is characterized by a decline in CD4?
cell count and immune function, which can
result in life-threatening opportunistic infections
(OI), HIV-related cancer and acquired
immunodeficiency syndrome (AIDS). HIV
represents a global pandemic affecting an
estimated 34 million individuals and causing
1.7 million deaths through AIDS or HIV-related
illness per year [1]. Currently, there is no cure
and, consequently, the aim of antiretroviral
(ARV) drugs is to control disease progression
through long-term inhibition of HIV replication.
During the last 25 years, six new classes of drugs
targeting different viral replication mechanisms
have emerged, allowing the introduction of new
antiretroviral therapies (ARTs) [2]. The use of a
combination of three or four ARTs, known as
highly active antiretroviral therapy, has resulted
in the gradual evolution of HIV from an acute
fatal disease into a chronic condition [3].
However, there remains a need for ARTs that
can sustain maximal virological suppression and
maintain excellent tolerability profiles without
compromising on efficacy or protection against
the development of resistance.
Dolutegravir (DTG), an integrase inhibitor
(INI), was developed to meet this need and was
approved in Canada in October 2013. TIVICAY
(ViiV Healthcare, Research Triangle Park, NC,
USA), in combination with other antiretroviral
agents, is indicated for the treatment of HIV-1
infection in adults and children 12 years of age
and older and weighing at least 40 kg. In
treatment-naive (TN) patients, DTG
demonstrated superiority over efavirenz (EFV)
and ritonavir-boosted darunavir (DRV/r) in
phase III randomized clinical trials (RCTs)
evaluating virological suppression (HIV
ribonucleic acid [RNA] \50 copies/mL) [4, 5].
A network meta-analysis (NMA) [6] supported
the finding that DTG resulted in a statistically
significant higher probability of virological
suppression and higher CD4? cell increase
from baseline at week 48 compared to all non-
nucleoside reverse transcriptase inhibitors
(NNRTIs) (EFV, rilpivirine [RPV]) and protease
inhibitors (PIs) (DRV/r, ritonavir-boosted
atazanavir [ATV/r], ritonavir-boosted lopinavir
[LPV/r]) of interest. A phase III RCT in TN
patients demonstrated non-inferiority of DTG
relative to raltegravir (RAL) [7]. In treatment-
experienced (TE) patients, a statistically
significantly higher proportion of patients
with virological suppression was reported in
the DTG arm (71%) compared to the RAL arm
(64%; P = 0.03). The safety profile of DTG is
comparable across ARVs, except for EFV having
a higher adverse event (AE) discontinuation rate
and DRV/r having a higher incidence of
diarrhea [7–10].
Decision makers evaluate new technologies
from clinical and economic perspectives; thus,
it is often necessary to demonstrate whether
new ARVs represent good value-for-money. This
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is assessed using cost-effectiveness (CE) analyses
that compare the relative costs and health
effects of two treatment strategies. The result
of this evaluation is expressed as a ratio in
which the denominator is a gain in health
(commonly measured in quality-adjusted life-
years [QALYs]) and the numerator is the cost
associated with the health gain. We present the
findings of the CE evaluation of DTG for the
treatment of TN and TE HIV-1 patients in the
Canadian setting using the Antiretroviral
Analysis by Monte Carlo Individual Simulation
(ARAMIS)-DTG model. ARAMIS-DTG was
developed to simulate the clinical evolution of
HIV and assess the CE of DTG compared to the
treatment options currently available. The
model’s structure was derived from the first
version of ARAMIS evaluating the CE of
maraviroc (MVC) ? optimized background
therapy (OBT) versus OBT alone [11], which
had been based on the cost-effectiveness of
preventing AIDS complications (CEPAC) model
[12]. In addition to updating model inputs to
reflect the changing nature of HIV, ARAMIS-
DTG included revised treatment algorithms for
TN and TE patients, explicitly considered AEs,
and explored the link between lipid levels and
the risk of cardiovascular disease (CVD) [13].
METHODS
Model Structure
ARAMIS-DTG adopted a microsimulation
approach, following individual patients
transitioning through mutually exclusive
health states using a monthly cycle length
time. The probability of disease progression
was continuously adjusted on individual
patient characteristics and the occurrence of
events such as virological failure, OI and/or AEs
(Fig. 1). Resource use and detriments to health-
related quality of life were driven by the levels
of CD4? cell count and accrued over an
individual’s lifetime. The model was developed
for Canada using the perspective of the publicly
funded healthcare system.
The population entering the model was
defined by age, gender, HIV-1 mRNA level,
CD4? cell count and covariates used in the
Framingham equation (systolic blood pressure,
diabetes, total cholesterol, and high-density
lipoprotein [HDL]) (Supplementary Appendix
2).
Depending on the treatment received,
patients faced a probability of experiencing
virological suppression (defined as viral load
suppression below 50 copies/mL at 48 weeks).
Virological suppression led to an increase in the
overall CD4? cell count, which continued to
increase as long as patients remained
virologically suppressed up to 5 years on
successful ART with a maximum possible value
of 1200 cells/lL. A steep increase during the first
2 months was assumed, with a slower rate of
increase considered afterwards according to
clinical trial evidence [14, 15]. The rate of
CD4? cell recovery was assumed to be
treatment specific and based on clinical trial
results.
If patients were not virologically suppressed,
they would move on to the next treatment
regimen following a treatment algorithm
derived for each of the comparators on the
basis of an advisory board of Canadian HIV
clinical experts. Treatment selection was based
on the previous treatment and the resistance
status (Supplementary Appendix 3).
After moving to the next treatment regimen,
patients would then face a probability of
experiencing virological suppression under the
new regimen. After failing a number of
treatments, patients were assumed to have
exhausted treatment options, which resulted
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in a decrease in the CD4? cell count using
natural history data and an approach detailed in
previously published CE models [16]. In this
approach, the CD4? cell count decline
contingent on viral load observed in an
untreated population from the Multicenter
AIDS Cohort Study [17] was corrected using
findings from the Swiss HIV Cohort, which
showed that no CD4? cell count decrease was
observed for treated patients with log10 viral
loads of four [18].
In addition to the virological suppression
rate derived from trials and the consequent
CD4? cell count increase/decrease, the
monthly rate of viral rebound after initial viral
suppression (commonly known as ‘‘late failure
rate’’) was considered from the second year
based on long-term evidence from clinical trials
[14, 19–25].
The ARAMIS-DTG model allowed up to six
successive ARTs for the TN analysis and four
successive ARTs for the TE analysis. The
number and subsequent efficacy of
successive ARTs were contingent upon the
resistance status. Resistance to nucleoside
reverse transcriptase inhibitors (NRTIs),
NNRTIs and INIs was explicitly included in
the first two lines of treatment in the TN
model and the first line of treatment in the TE
model.
The TN model included nine categories of
acute AEs in the analysis (diarrhea, nausea,
vomiting, rash, nightmares/abnormal dreams,
dizziness, depression, insomnia, other AEs). For
all AEs, a probability of severity (grade 2–4) and
discontinuation due to the AE were considered
using clinical trial evidence. In the TE analysis,
as there were no observable differences between
the safety profiles of DTG and RAL, only
discontinuations due to AEs were considered.
Cardiovascular disease was modeled as a
monthly risk determined by a Framingham
equation (predicting coronary heart disease
and stroke). No relationship was assumed
between CD4? cell count and risk of CVD, but
the effect of treatment on lipids (total
cholesterol and HDL) as observed in clinical
trials was considered in the risk equation.
Fig. 1 The interaction between treatment, viral load and CD4? cell count. AE adverse event, CVD cardiovascular disease,
OI opportunistic infection, QALY quality-adjusted life-year
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Mortality was modeled using four main
causes of death: HIV, acute OIs, CVD and all-
cause mortality. HIV mortality was stratified by
CD4? cell count according to natural history
data and corrected to account for the benefits of
ART [26, 27]. The all-cause mortality rate
(excluding HIV- and CVD-related death) was
multiplied by a gender-specific standardized
mortality ratio from the British Columbia
Centre for Excellence (BC-CfE) cohort (Data
on file, GlaxoSmithKline. Result tables. Cohort
characteristics and mortality in HIV? patients.
HO-13-13512. 2013) [28]. This was applied to
account for the fact that HIV patients are
expected to have an increased risk of death
from other causes related or not to different risk
factors [4].
The main model outcomes were (1) total
costs, (2) QALYs, (3) incremental cost-
effectiveness ratios (ICERs) and (4) clinical
endpoints (occurrence of OI, cause of death,
progression to AIDS, AIDS-free survival,
treatment history, time on ART, time on
successful therapy, and time on failing therapy).
The model was developed in Microsoft Excel
2007 with Visual Basic for Applications code
embedded, and results presented are based on
500,000 simulations. Costs and health
outcomes were discounted at a rate of 5% and
no half-cycle correction was applied as the cycle
length was small relative to the time horizon
(about 30 years in TN patients and 20 years in
TE patients).
Model Inputs
All the data sources used for the model (global
and local sources) are summarized in Table 1.
Efficacy Parameters
The efficacy data applied to the TN and TE
models are presented in Supplementary
Appendix 4. The DTG phase III clinical trial
program was the main source of efficacy data for
both analyses. In TN patients, the SINGLE trial
(ClinicalTrials.gov # NCT01263015) evaluated
DTG relative to EFV [4], the SPRING-2 trial
(ClinicalTrials.gov # NCT01227824) compared
DTG to RAL [7], and the FLAMINGO trial
(ClinicalTrials.gov # NCT01449929) compared
DTG to DRV/r [5]. The NMA in TN patients was
used to derive efficacy parameters for other
comparators when direct head-to-head data
were unavailable such as for RPV,
elvitegravir/cobicistat (EVG/cobi), ATV/r and
LPV/r [6]. For the TE INI-naive population
comparing DTG to RAL, data were obtained
from the SAILING trial (ClinicalTrials.gov #
NCT01231516) [8].
Where data were unavailable after 1 year for
comparators, identical efficacy was considered
for DTG and the comparator, and identical
efficacy parameters were applied to each
subsequent regimen, with values obtained
from various sources of published clinical
evidence and validated by clinical experts.
After the trial period, evidence from the
STARTMRK trial (ClinicalTrials.gov #
NCT00369941) was used for all treatments to
inform the late failure rate and CD4? cell count
increase of patients who maintained virological
suppression on their initial treatment [19].
Costs of ART
The costs of ART were obtained from the
Ontario Drug Benefit e-formulary [29]. Dosages
used reflected those approved in Canada as
indicated in the product monographs. In the
TN model, the cost for the backbone as first-line
treatment with the third-line agents was based
on a blend of Truvada (tenofovir/emtricitabine
[TDF/FTC]; Gilead Sciences, Foster City, CA,
USA) and Kivexa (abacavir [ABC]/lamivudine
[3TC]; ViiV Healthcare, Research Triangle Park,
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NC, USA). The proportion of each of these was
based on the clinical trials for DTG (40/60%,
respectively) [5, 7, 9] and market shares for the
comparators (57/43%, respectively) (Data on
file, GlaxoSmithKline. HIV lines of therapy
analysis refresh results v2.0. 2013.). For
comparators typically used only as fixed-dose
combinations (FDC; i.e., EFV, RPV and
EVG/cobi), the cost of the FDC was used. In
the TE model, the cost of the concomitant
Table 1 Global and local inputs in the model
Model input Global data source
(including clinical trials)
Local data source
Efﬁcacy ﬁrst ART: viral suppression, CD4?






Efﬁcacy subsequent ART: viral suppression,






Safety data SPRING-2, SINGLE, FLAMINGO,
SAILING, NMA [5–9]
–
Baseline demographic and disease




Clinical comparator and treatment
algorithm
– Advisory board of Canadian HIV
clinical experts
Treatment policy (tests, OI prophylaxis) DHHS guidelines [30] –
Costs (ART, tests, HIV, AE, OI, CVD,
death)
– Ontario Drug Beneﬁt e-formulary,
Krentz, Anis, Fassbender,
Smolderen [29, 31–34]
Background mortality – Statistics Canada [28]
SMR HIV all-cause mortality vs. general
population
– BC-CfE
Incidence and prevalence OI d’Arminio Monforte [35] –
Lipids SPRING-2, SINGLE, FLAMINGO,
NMA [5–9]
–
Utilities Franks [36], SPRING-2, SINGLE,
FLAMINGO, Kauf, Paltiel
(SA only) [5, 7, 9, 37, 38]
Isogai [39]
HIV mortality MACS, Cole [17, 27] –
AE adverse event, ART antiretroviral therapy, BC-CfE British Columbia Centre for Excellence, CVD cardiovascular disease,
DHHS Department of Health and Human Services, HIV human immunodeﬁciency virus, MACS Multicenter AIDS
Cohort Study, NMA network meta-analysis, OI opportunistic infection, SA sensitivity analysis, SMR standardized mortality
ratio
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therapy (i.e., OBT) was based on a combination
of DRV/r and TDF, the most prevalent regimen
in the SAILING trial.
The cost of salvage therapy was based on
market shares in fifth-line ART excluding all
NRTIs except TDF, EFV and Atripla (EFV/TDF/
FTC; Bristol-Myers Squibb, New York, NY, USA,
and Gilead Sciences) and considering that the
regimen would include one ritonavir-boosted PI
and two other treatments to be chosen among
RAL, ETR, MVC and TDF (IMS Brogan, a unit of
IMS Health, Danbury, CT, USA) (Data on file,
GlaxoSmithKline. HIV lines of therapy analysis
refresh results v2.0. 2013.) on the basis of expert
opinion. Estimated cost of salvage was applied
to both arms equally. The costs of all ART
regimens for each line of treatment of the
model are detailed in Table 2.
Healthcare Costs
The costs of HIV care in Canada were derived
from a study by Krentz et al. [31], which reported
the cost of medical care for HIV patients from
the Southern Alberta Cohort between April 1997
and April 2006. These costs included outpatient
care only (HIV clinic visits, HIV-related specialist
visits, non-HIV physicians, laboratory tests
[CD4? cell count tests, viral load, HIV
genotypic resistance testing, serological tests,
hematology, and routine chemistry]). It was
assumed that all inpatient stays and emergency
room visits were included within the cost of OIs
and pre-terminal costs, which were taken from a
study by Anis et al. [32, 33]. Neither genotypic
resistance testing nor human leukocyte antigen
testing was explicitly considered in the model to
avoid double counting. All costs considered in
the model were inflated to 2013 values
considering consumer price index (health and
personal care index).
Utilities
Utilities applied to each CD4? cell count strata
were derived from a study by Isogai et al. [39],
which examined the relationship between
Health Utility Index-3-derived health
preference score and HIV health status
measured by CD4? cell count (Table 2).
Disutilities applied to patients developing CVD
were derived from Franks et al. [36] and applied
using a multiplicative relationship. Disutilities
associated with AEs and OIs were not
considered in the base case but were explored
in sensitivity analyses using published evidence
[37, 38] (Table 2).
Sensitivity Analyses
The uncertainty was investigated through both
univariate and structural sensitivity analyses.
Univariate analyses focused on parameters
expected to impact model results, with ranges
defined by estimates of variance (e.g.,
confidence intervals) or based on clinical
expert-validated assumptions. These included
the uncertainty surrounding the three efficacy
parameters (virological suppression at week 48,
late failure between week 48 and week 96, and
CD4? cell count increase at week 48)
(Supplementary Appendix 2); the efficacy of
subsequent treatment lines (±5%); the costs of
subsequent treatment lines (±10%); and the
cost of salvage treatment (±25%). Structural
sensitivity analyses were defined to evaluate the
robustness of the model when modifying basic
model assumptions—modifying the backbone
for DTG (100% Truvada or 100% Kivexa), the
absence of resistance development for DTG and
its comparators, using alternative data for
utilities, or using alternative discount rates
(0% and 3%).
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Table 2 Costs and utilities
Costs Monthly costs (Can$ 2013) Source
ART (TN model)
First line Ontario Drug Beneﬁt e-formulary [29]
Market shares (IMS Brogan) Advisory boardDTG ? 2 NRTIs 1326.79
Atripla 1296.39
RAL ? 2 NRTIs 1604.89
DRV/r ? 2 NRTIs 1486.86
Complera 1266.16
Stribild 1383.81
ATV/r ? 2 NRTIs 1519.03





First line Ontario Drug Beneﬁt e-formulary [29]
Market shares (IMS Brogan)DTG ? DRV/r ? TDF 1825.43
RAL ? DRV/r ? TDF 2083.83
Second line 2322.25
Salvage 2370.95
HIV, CD4? cell count (cells/lL)












Death (last 3 months) 23,667 Fassbender [33]
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Table 2 continued
Costs Monthly costs (Can$ 2013) Source
Cardiovascular disease 4272 Smolderen [34]
Adverse events








Other adverse events 0
Utility
HIV utility (regression coefﬁcients)









Utilities used in sensitivity analyses
Trial-based utilities CD4 Utility EQ-5D utilities, available from SPRING-2,
SINGLE and FLAMINGO[200 0.880
50–100 0.850
0–50 0.830
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Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by




In the TN analysis, DTG was found to be the
dominant strategy (i.e., more clinically effective
and cost saving) compared with all other
treatments considered (Table 3). This result
was driven by its superior efficacy in virologic
suppression (vs. all comparators except RAL),
better resistance profile (vs. EFV, RPV, RAL and
EVG/cobi), and/or lower drug acquisition cost
(vs. RAL, DRV/r, and ATV/r). Patients were
estimated to stay on DTG for approximately
20 months longer than those receiving EFV,
10 months longer versus DRV/r and EVG/cobi
and 7 months longer versus RAL. Fewer DTG
patients developed AIDS (32% vs. 37% in those
treated with EFV, 34% vs. DRV/r and RAL, 35%
vs. EVG/cobi). There was an additional
3–8 months of AIDS-free survival in the DTG
Table 2 continued
Costs Monthly costs (Can$ 2013) Source















AE adverse event, ART antiretroviral therapy, ATV/r ritonavir-boosted atazanavir, CVD cardiovascular disease, DRV/r
ritonavir-boosted darunavir, DTG dolutegravir, HIV human immunodeﬁciency virus, LPV/r ritonavir-boosted lopinavir,
NRTI nucleoside reverse transcriptase inhibitor, OI opportunistic infection, RAL raltegravir, TDF tenofovir, TE treatment-
experienced, TN treatment-naive
346 Infect Dis Ther (2015) 4:337–353
arm. The incremental gain in QALYs over a
lifetime ranged from 0.041 (vs. RAL) to 0.132
(vs. EFV). Life expectancy ranged from 27.1 to
27.6 years (given a cohort age of 36.5 years at
model entry), and incremental life gains
associated with the DTG strategy ranged from
2 months (vs. RAL) to 6 months (vs. EFV). A
lower incidence of AIDS was estimated among
Table 3 Cost-effectiveness results for DTG in TN and TE Patients
Treatment DTG Comparator Difference ICER
TN model
EFV (Atripla) Cost (Can$ 2013) 315,086 322,821 -7735
LY 27.60 27.13 0.47
QALY 10.620 10.487 0.132 Dominant
RAL Cost (Can$ 2013) 312,943 341,516 -28,572
LY 27.56 27.39 0.17
QALY 10.593 10.552 0.041 Dominant
DRV/r Cost (Can$ 2013) 312,128 331,221 -19,093
LY 27.59 27.38 0.22
QALY 10.607 10.537 0.070 Dominant
RPV (Complera) Cost (Can$ 2013) 315,086 316,479 -1393
LY 27.60 27.18 0.42
QALY 10.620 10.506 0.114 Dominant
EVG (Stribild) Cost (Can$ 2013) 312,943 323,918 -10,975
LY 27.56 27.28 0.28
QALY 10.593 10.515 0.078 Dominant
ATV/r Cost (Can$ 2013) 312,128 334,860 -22,732
LY 27.59 27.29 0.30
QALY 10.607 10.508 0.100 Dominant
LPV/r Cost (Can$ 2013) 312,128 330,877 -18,750
LY 27.59 27.22 0.38
QALY 10.607 10.492 0.116 Dominant
TE model
RAL Cost (Can$ 2013) 353,957 357,702 -3745
LY 19.57 18.97 0.60
QALY 8.255 8.033 0.222 Dominant
ATV/r ritonavir-boosted atazanavir, DRV/r ritonavir-boosted darunavir, DTG dolutegravir, EFV efavirenz, EVG
elvitegravir, ICER incremental cost-effectiveness ratio, LPV/r ritonavir-boosted lopinavir, LY life-year, QALY quality-
adjusted life-year, RAL raltegravir, RPV rilpivirine, TE treatment-experienced, TN treatment-naive
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DTG-treated patients, with reductions ranging
from 1.5% (vs. DRV/r) to 4.7% (vs. EFV). The
lifetime cost savings against all comparators
ranged from Can$1393 to Can$28,572.
Sensitivity Analyses
These results appear to be fairly robust to
variations in any of the model inputs in
sensitivity analyses, which contributed to
increased confidence in the base case
estimates. The only sensitivity analysis under
which DTG stopped being dominant was the
use of generic EFV ? Truvada instead of Atripla.
In any case, for this analysis, DTG was still
within the range normally considered cost-
effective with an ICER of Can$44,604/QALY
gained (Supplementary Appendix 5–7).
HIV-1 TE Patients
Base Case
For the TE model, DTG was also the dominant
strategy over RAL (Table 3). Because of the
increased efficacy observed in the SAILING
trial, there was a considerably greater lifetime
incremental QALY gain for DTG compared to
RAL (0.222 QALY). Patients were estimated to
stay on DTG for approximately 4 months
longer, and live approximately 7 months
longer, than those receiving RAL. Fewer DTG
patients developed AIDS (73% compared with
74.6% of those treated with RAL) and there was
an additional 4 months of AIDS-free survival in
the DTG arm. DTG-related lifetime savings
(amounting to Can$3745 discounted) were
primarily related to the lower drug acquisition
cost of DTG versus RAL and the delay in
progression to more expensive treatment lines;
these were partially offset by additional costs
due to the extended survival achieved by DTG
patients.
Sensitivity Analyses
Again, these results in the TE analysis were
robust to variations in any of the model inputs
in sensitivity analyses, which contributed to
increased confidence in the base case estimates.
DTG remained dominant in all scenarios,
including the use of a discounted price for
RAL (Can$23/day). The sole exception to
dominance occurred with the elimination of
the discount rate (for costs and effects), but the
estimated ICER (Can$11,787) is well within the
range for a drug to be considered cost-effective
(Supplementary Appendix 8).
DISCUSSION
This analysis demonstrates that, in the
perspective of the publicly funded healthcare
system, DTG is more effective and less costly in
the management of both TN and TE patients
infected with HIV when compared to the most
widely used agents.
Treatment with DTG resulted in incremental
QALY gains ranging from 0.041 (vs. RAL) to
0.132 (vs. EFV) over a lifetime in the TN
population and a 0.222 incremental QALY
gain when compared to RAL in TE patients.
The benefits in clinical outcomes were primarily
related to the superior efficacy of DTG versus
most of the comparators ([7% in viral
suppression at 48 weeks vs. all comparators,
except RAL and EVG/cobi in TN) and/or the
prevention of the development of resistance to
NRTIs, NNRTIs or INIs (vs. EFV, RAL, RPV and
EVG/cobi). However, it should be noted that the
conservative assumption on the high efficacy of
subsequent treatments meant that patients were
kept controlled with high CD4? cell count
levels after their first failure. As a result, the
clinical benefit of delaying the switch from the
initial treatment only materialized at a late
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stage in a patient’s life when it resulted in an
increase in life expectancy. This meant that
most clinical benefits associated with DTG were
accrued later and were consequently affected by
the applied discount rate.
The estimated lifetime costs for patients
initially treated with DTG were less than those
for patients initially treated with any other
comparator. In the TN analysis, the use of DTG
as the first ART resulted in cost savings to the
healthcare system over a lifetime ranging from
Can$1393 (vs. RPV) to Can$28,572 (vs. RAL).
The estimated savings were related to lower
drug acquisition costs (vs. RAL or ATV/r) or
delays in the use of expensive therapy after
multiple failures. In the TE population, lower
lifetime costs for patients treated with DTG
were mainly due to lower drug acquisition costs.
These savings in TN and TE patients were
partially offset by the treatment costs
associated with an increase in survival
associated with DTG. The additional total
costs for treatments that prolong life are an
issue previously reported in published CE
models in HIV [41]. Obtaining lifetime savings
despite these additional costs means that the
economic benefits associated with the DTG
strategy are very strong. The CE results
presented in this report were shown to be
robust in sensitivity analyses. The most
influential parameters on the CE of DTG were
the acquisition cost for EFV, the choice of the
utility source, discount rates, suppression rates
at 48 weeks (vs. DRV/r), resistance assumptions
(vs. RAL or EFV), and cost of salvage therapy (vs.
EFV). However, a change in values for any of
these parameters still rendered DTG as the
dominant strategy in almost all the sensitivity
analyses performed. When DTG stopped being
dominant, the resulting ICER was still within
the acceptable range for Canada. A conservative
approach was adopted by considering the price
of the multiple-pill regimen instead of the
cheaper fixed-dose combination for DTG.
The approximate life expectancy for patients
in the ARAMIS-DTG model was 27–28 years and
20 years for the TN and TE populations,
respectively. This is slightly higher than that
reported in recently published economic
evaluations analyzing HIV populations in
western countries: CE analyses of RPV and
EVG/cobi and analyses based on the CEPAC
model reported survival of 11.4–26.5 years in
patients initiating ART [42–46]. However, with
the increasing efficacy and tolerability of ART,
life expectancy reported in the literature may
underestimate the current life expectancy of
HIV patients initiating ART. For TE patients, the
literature estimates vary considerably and range
from 8.9 to 29 years. The absolute number of
QALYs accrued following ART treatment in
ARAMIS-DTG over a lifetime was estimated to
be 10.49–10.62, similar to the magnitude of
QALYs gained reported in other recently
published economic evaluations in western
countries (7.2–15.0 QALYs gained) for RAL,
RPV, generic EFV and EVG/cobi [44, 47–49].
Two validation exercises were conducted
with ARAMIS-DTG to assess the convergent
validity of ARAMIS related to the modeling of
long-term outcomes of HIV and to assess its
real-life predictive power. Firstly, a
corroboration exercise between ARAMIS-DTG
and CEPAC was conducted using published
CEPAC study data [42]. The published CEPAC
input parameters were used to populate
ARAMIS-DTG, and life expectancy estimates
were then compared across models by gender,
ethnic groups and late presentations.
Furthermore, the impact of structural
differences, such as OI and HIV mortality
rates, and correction of the HIV mortality for
ARV exposure and risk behaviors were assessed
between the models one by one and
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simultaneously. When using the same inputs,
ARAMIS-DTG provided similar estimates of life
expectancy to those from CEPAC (23.20 vs.
22.66 years, respectively). Differences in life
expectancy ranged from -1.38 to ?2.56 years
depending on the subgroups analyzed. The
main difference between ARAMIS and CEPAC
assumptions appeared to lie in the gender- and
ethnic-specific adjustment for risk behaviors,
which decreased the life expectancy estimates
by 2.61 years relative to the base case. However,
all other variations detected between the two
models were within 10% of the absolute life
expectancy for the overall population and in
nearly all subgroups analyzed.
A second validation exercise compared the
incidence of OI and the CD4? cell count
restoration from ARAMIS-DTG with those from
an observational cohort of patients initiating
ART in the BC-CfE program between 2008 and
2011 (Data on file, GlaxoSmithKline. Result
tables. Cohort characteristics and mortality in
HIV? patients. HO-13-13512. 2013). Baseline
population characteristics, patient follow-up and
treatment efficacy were modified to reflect the
observational cohort in the model, and mean
changes in CD4? cell count and incidence rates
of AIDS-related events were simulated in
ARAMIS-DTG. In particular, the suppression
rate at 48 weeks and late failure rates were
adjusted to replicate the time on treatment
observed in the BC-CfE cohort. The impact of
relevant ARAMIS parameters on these outcomes,
such as mortality or virological suppression, was
assessed in sensitivity analyses. In the base case
analysis, the average CD4? cell count over five
years increased from 295 to 682 cells/lL in
ARAMIS-DTG and from 303 to 532 cells/lL in
the BC-CfE cohort, reflecting a potential
overestimation of adherence in the clinical trial
setting. However, despite a higher CD4? cell
count, the incidence of AIDS-related events was
also higher in ARAMIS: 3.81 vs. 2.84 per 100,000
person-years, which suggests that the higher
incidence of AIDS-related events in ARAMIS-
DTG was mostly attributable to the pre-2005
rates used to inform the model; including a
CD4? restoration rate and OI incidence that
reflect recent real-life evidence might further
increase the validity of the ARAMIS-DTG model.
However, the model still possesses some
limitations. Laboratory testing was not
explicitly measured as it could not be separated
out from overall HIV care costs per CD4? cell
count presented in Krentz et al. As DTG was
associated with a longer time on treatment and a
delayed time to switching therapy, not
considering test costs separately arguably
resulted in underestimation of the savings due
to fewer resistance tests in the DTG arm.
Productivity costs were not included because of
the lack of recent data in Canada, but including
these would have reinforced the savings
associated with DTG. The higher efficacy
observed for DTG is translated to a lower
proportion of patients with a CD4? cell count
lower than 200 cells/lL and, consequently, in a
lower risk of OIs, which are directly associated
with productivity losses [50, 51].
A complex treatment algorithm was
designed to account for the consequences of
class resistance on the number of available
strategies and their efficacy. This part required
simplifications that are necessary in all CE
models as it cannot represent the diversity of
the parameters considered when selecting
another regimen after virologic failure.
Furthermore, the number of remaining
strategies is a structural assumption in the
model, and their efficacy was derived from
selected clinical trials. However, the sensitivity
analysis removing the impact of resistance on
the choice of the next treatment did not alter
the conclusions of the CE analysis.
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CONCLUSION
DTG fulfills a clinical need among patients
infected with HIV across the whole spectrum
of the disease by offering high-level efficacy
combined with advantages in tolerability and a
high barrier to resistance. This economic
evaluation demonstrated that DTG is more
effective and less costly (i.e., economically
dominant) in the management of TN and TE
HIV patients when compared to recommended
treatments in the Canadian setting.
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